Oral vernakalant: Phase III delayed

Cardiome said partner Merck will delay the start of Phase III testing for oral vernakalant, which had been expected to start this summer. Cardiome did not provide a reason for the delay and will provide updated guidance once Merck has finalized the clinical development plan for the mixed ion channel antagonist. Merck would not disclose further details. ...